军事知识服务平台
激素受体阳性乳腺癌单纯骨转移的预后因素及不同治疗策略结果分析
Prognostic factors and analyses of different therapeutic strategies in HR + breast cancer patients with bone-only metastases
摘要 目的 探讨激素受体阳性乳腺癌单纯骨转移患者的最佳治疗策略和预后因素.方法 收集2005年1月至2010年10月中国医学科学院肿瘤医院诊治的139例激素受体阳性乳腺癌单纯骨转移患者的资料,回顾性分析其临床病理特征,探讨不同治疗策略和临床因素对预后的影响,同时分析不同治疗策略对骨相关事件的影响.结果 139例患者中,接受一线化疗者99例,一线内分泌治疗者40例.139例患者中位总生存期为61个月,两组5年生存率差异无统计学意义(HR=0.687,P =0.362).单因素分析结果提示无病生存期>3年(HR=0.333,P=0.014)、淋巴结转移<10个组患者(HR =0.239,P=0.001)预后较好,在COX多因素回归分析它们仍是预后良好因素.一线化疗组总骨相关事件发生率较一线内分泌治疗组低,分别为45.4%(45/99)与62.5% (25/40),但差异无统计学意义(P=0.092).结论 术后无病生存期>3年、淋巴结<10个是激素受体阳性乳腺癌单纯骨转移患者独立的预后良好因素.这类患者一线无论选择内分泌治疗还是化疗,对总生存影响不明显,但一线化疗可能有助于减少骨相关事件.
Abstract:
Objective To explore the therapeutic outcomes of various first-line regimens and prognostic factors for hormone receptor positive (HR +) breast cancer (BrCa) patients with bone-only metastases.Methods A total of 139 HR + BrCa patients with bone-only metastases between January 1,2005 and October 31,2010 were retrospectively reviewed.Their clinicopathologic characteristics,various treatment regimens and clinical survival factors were analyzed.Furthermore,the effects of various therapeutic regimens on skeletal-related events (SREs) were explored.Results In this cohort,99 patients received first-line chemotherapeutic regimens and 40 had first-line endocrine drugs.Their median overall survival time was 61 months.No significant difference was noted in 5-year overall survival rate between first-line chemotherapy group (49.4%) and first-line endocrine group (44.3%) (hazard ratio (HR) 0.687,95% confidence interval (CI) 0.307-1.539,P =0.362).Furthermore,interval of disease-free survival >3 years and number of positive lymph nodes < 10 were favorable prognostic factors by univariate analyses (HR =0.333,95% CI 0.138-0.803,P =0.014; HR =0.239,95% CI 0.102-0.562,P=0.001) ; they were also independent favorable prognostic factors by multivariate Cox-regression analyses.The proportion of patients with SREs decreased in the first-line chemotherapy group compared with the first-line endocrine group (45/99 (45.4%) vs 25/40 (62.5%)).Nonetheless,the difference was insignificant (P =0.092).Conclusion Interval of disease-free survival > 3 years and number of positive lymph nodes <10 are independent favorable prognostic factors.The overall survival of HR + BrCa patients with bone-only metastases is not significantly different between two groups.First-line chemotherapy may lower the incidence of SREs.Both endocrine therapy and chemotherapy are effective for HR + BrCa patients with bone-only metastases and they should be individualized.
Author: DING Xiao-yan FAN Ying MA Fei LI Qing WANG Jia-yu YUAN Peng ZHANG Pin XU Bing-he
作者单位: 中国医学科学院北京协和医学院肿瘤医院肿瘤研究所内科, 北京,100021
刊 名 中华医学杂志 ISTICPKU
年,卷(期): 2012, 92(46)
机标分类号: R737.9 R155.5 R242
在线出版日期: 2013年2月28日